Drug Combination Details
| General Information of the Combination (ID: C15497) | |||||
|---|---|---|---|---|---|
| Name | Aloin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TG2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TYR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | B16-F10 | CVCL_0159 | Mouse melanoma | Mus musculus | ||
| Experimental
Result(s) |
Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation. Amino Acids. 2013 Jan;44(1):293-300. | |||
